Immune Checkpoint Inhibitors: The Good, the Bad, and the Emerging Field of Cardio-Oncology

Liver Transplantation: Where Are We Now and Where Are We Going?Подробнее

Updating Our Cardio-Oncology Skills in the Cancer Immunotherapy Era: Management of Cardiac irAEsПодробнее

2021-10 Beyond Chemo: Toxicity of Anticancer Immune Checkpoint Inhibitors (Andrew Stolbach)Подробнее

JACC: CardioOncology Video Case Presentation | Early Immune Checkpoint Inhibitor CardiotoxicityПодробнее

Acute and Chronic Cardiac and Vascular Effects of Contemporary Immune Therapies for CancerПодробнее

Cancer Immune Checkpoint InhibitorsПодробнее

Cardiac Troponins and Checkpoint InhibitorsПодробнее

Cardio-Oncology in 2019Подробнее

Advanced Cardiac Imaging Among Patients with Cardiovascular Complications From Cancer ImmunotherapyПодробнее

Autoimmune Complications from Cancer Chemotherapy: An Emerging FieldПодробнее

SITC clinical practice guidelines on immune checkpoint inhibitor-related adverse eventsПодробнее

Cardio-oncology: an emerging field within cancer treatmentПодробнее

Immunotherapy/Checkpoint Inhibitor, Targeted Immunotherapy Drugs 5/2/18Подробнее

Cardio-Oncology Spotlight: Dr. Nicolas Palaskas Treating ICI MyocarditisПодробнее

CV Impact of Immune Checkpoint Inhibitor CardiotoxicityПодробнее

Dr. Javid Moslehi: Why cardiologists must care about cancer immunotherapyПодробнее

Targeting the immune system with checkpoint inhibitorsПодробнее

Improving the Management of Cardiac Immune-Related Adverse Events in Patients With CancerПодробнее

Cardiotoxicity from Immunotherapy: Can Advanced Cardiac Imaging Meet the Challenge?Подробнее

Cardiac Complications of Emerging Cancer TherapeuticsПодробнее

Drs. Moslehi & Johnson discuss Cardiac irAEs updates from #AHA21: https://bit.ly/31LJaP3Подробнее